Pittsburgh Actos Bladder Cancer Lawsuits May Soon Settle
UPDATE: THIS CASE HAS SETTLED. Read more about the Actos bladder cancer lawsuit. Don’t delay – the case has just settled, affected patients and their families must retain a lawyer by May 1, 2015 to participate in this $2 Billion settlement.
As Pittsburgh lawyers actively handling Actos bladder cancer lawsuits Lupetin & Unatin is optimistic that our clients’ cases may soon settle for money compensation. Takeda, the maker of Actos, has offered $2.2 Billion for settlement of all current Actos bladder cancer lawsuits including Pittsburgh Actos lawsuits as reported by Bloomberg here. If this settlement were accepted, it would result settlements for Pittsburgh patients with bladder cancer after taking diabetes drug Actos in the range of $275,000 per patient.
Actos (pioglitazone) is a member of a controversial class of drugs known as thiazolidinediones. Since 2007, Actos has been one of the most popular drugs for treating Type 2 diabetes. Actos has been sold since 1999 and its side effects are still being studied.
In 2012 a large cohort study of Actos was done. This study showed that Actos was associated with an increased rate of bladder cancer. The rate of bladder cancer from Actos increased the longer patients took Actos. The highest rate of bladder cancer was seen in patients that had taken Actos for more than two (2) years. For patients that have taken or are taking Actos, the conclusion of the study is that Actos is associated with an increased risk of bladder cancer among people with type 2 diabetes.
Though the Actos lawsuit settlement has not been finalized it could happen any time. Anyone in Pittsburgh with Type II diabetes who as been diagnosed with bladder cancer after taking Actos are encouraged to contact Lupetin & Unatin to file their claims as soon as possible.
Even though actos is the most preferred drug. It is well known fact that the drug has got severe side effects.
I pay a quick visit everyday a few blogs and blogs to read posts, but
this webpage provides quality based content.